Mean nuclear volume: a supplementary prognostic factor in endometrial cancer

Citation
O. Mogensen et al., Mean nuclear volume: a supplementary prognostic factor in endometrial cancer, INT J GYN C, 9(1), 1999, pp. 72-79
Citations number
24
Categorie Soggetti
Reproductive Medicine
Journal title
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
ISSN journal
1048891X → ACNP
Volume
9
Issue
1
Year of publication
1999
Pages
72 - 79
Database
ISI
SICI code
1048-891X(199901/02)9:1<72:MNVASP>2.0.ZU;2-O
Abstract
We evaluated the following nine parameters with respect to their prognostic value in females with endometrial cancer: four stereologic parameters [mea n nuclear volume (MNV), nuclear volume fraction, nuclear index and mitotic index], the immunohistochemical expression of cancer antigen (CA125) and th e postsurgical stage (P-stage), the malignancy grade, the depth of myometri al tumor invasion and the age of the female. Tissue was obtained from 68 co nsecutive endometrial cancer patients with clinical FIGO stage I tumors who were registered in the Danish endometrial cancer study (DEMCA). The primar y operation included total abdominal hysterectomy and bilateral salpingo-oo phorectomy. All patients underwent radical operations. The tumors were clas sified postsurgically as P-stage I-III. All patients received the same post operative radiation therapy. The surviving patients were observed for a med ian of 6.4 years (range 5.0-8.4 years). Cox regression analysis (automatic forward selection) showed the MNV to be the most significant prognostic par ameter followed by the P-stage. Patients who had localized tumors or tumors with small nuclei had a better probability of surviving than did women wit h advanced tumors or tumors with large nuclei. No significant relationship between survival and the remaining seven parameters was demonstrated. This first investigation of the prognostic value of the MNV in females with endo metrial cancer demonstrates that it may assist the distinction between thos e patients who can be cured by hysterectomy alone and those who need adjuva nt therapy.